is retatrutide a triple agonist Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% Retatrutide Obesity Triple Agonist Targeting

Retatrutide (also referred to in research literature as LY3437943) is an investigational triple hormone receptor agonist currently in clinical development

For adults with a BMI of 40 kg/m2 or higher or those with a BMI of 35 kg/m2 or higher with obstructive sleep apnea or prediabetes, Apovian recommends strongly considering bariatric surgery as a first-line therapy due to very low complication rates and robust and durable weight loss

These drugs mimic the action of natural GLP-1, enhancing its beneficial effects on weight and blood sugar control

The claims floating online are largely anecdotal and should be treated as such until further scientific research is conducted.

Under expert supervision, the program aims to help citizens establish sustainable lifestyle patterns and achieve long-term weight management goals in a safe and effective manner